Skip to main content

Advertisement

Table 2 Baseline characteristics of the patients in the included studies

From: Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis

Study ID n (MSCs/placebo) Male, n (MSCs/placebo) Age, years (MSCs/placebo) Protopathy NHYA class (MSCs/Placebo) Hypertension, n (MSCs/placebo) Diabetes, n (MSCs/placebo) BMI (MSCs/placebo)
Wang JA 12/12 NA NA DCM NA NA NA NA
Heldman AW 19/11 18/10 57.1 ± 10.6/60.0 ± 12.0 ICM 2/2* 12/6 3/3 NA
Zhao XF 30/29 24/19 52.9 ± 16.32/53.21 ± 11.46 DCM and ICM NA NA NA NA
Mathiasen AB 40/20 36/14 66.1 ± 7.7/64.2 ± 10.6 ICM 29/15* NA 15/3 29.8 ± 4.7/28.7 ± 5.3
Xiao W 17/20 12/14 51.6 ± 12.2/54.4 ± 11.6 DCM NA 4/7 5/6 NA
Butler J 22 13 47.3 ± 12.8 NICM 1* NA 5 NA
Perin 45/15 44/11 62.2 ± 10.3/62.7 ± 11.2 DCM and ICM 14/9* 29/9 13/2 29.8 ± 4.1/31.3 ± 9.2
Bartolucci J 15/15 12/14 57.33 ± 10.05/57.2 ± 11.64 DCM and ICM 2.03 ± 0.61/1.67 ± 0.49 7/8 5/7 29.12 ± 2.88/29.52 ± 4.0
Bartunek J 120/151 107/136 61.6 ± 8.6/62.1 ± 8.7 NA 96/114* NA NA 28.2 ± 3.7/28.6 ± 4.4
  1. NHYA New York Heart Association, BMI body mass index, DCM dilated cardiomyopathy, ICM ischemic cardiomyopathy, NICM non-ischemic cardiomyopathy, NA not available
  2. *Indicate the number of patients with NHYA class III